Type 2 diabetes is a chronic disease that affects millions of people worldwide, and its prevalence is on the rise. It is associated with long-term complications such as heart disease, stroke, kidney disease, and nerve damage, among others.
The condition is characterized by high blood sugar levels due to the body’s inability to use insulin effectively. The disease is managed through lifestyle changes, medication, and regular monitoring of blood glucose levels.
New drug development for type 2 diabetes
The past decade has seen significant advancements in drug development for type 2 diabetes. A range of new drugs have been introduced that help manage blood sugar levels better than ever before.
These drugs work by targeting different pathways and mechanisms involved in the development of type 2 diabetes. Some of the recent drug developments include:.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors
SGLT2 inhibitors are a class of drugs that block glucose reabsorption in the kidneys and increase glucose excretion in urine. They lower blood sugar levels and help with weight loss by reducing caloric absorption.
These drugs have also been shown to reduce the risk of heart disease and kidney failure in people with type 2 diabetes. Examples of SGLT2 inhibitors include canagliflozin, dapagliflozin, and empagliflozin.
Glucagon-like peptide-1 (GLP-1) receptor agonists
GLP-1 receptor agonists are a class of injectable drugs that stimulate the production of insulin and inhibit the release of glucagon. These drugs also slow down the rate at which food is digested, reducing blood sugar spikes after meals.
Related Article
New medication controls blood glucose levels and reduces weight in type 2 diabetes patients
They have been shown to promote weight loss and reduce cardiovascular risk in people with type 2 diabetes. Examples of GLP-1 receptor agonists include exenatide, liraglutide, and semaglutide.
Dipeptidyl peptidase-4 (DPP-4) inhibitors
DPP-4 inhibitors are oral drugs that increase levels of GLP-1 and insulin in the body. They reduce blood sugar levels and improve glucose control in people with type 2 diabetes. They have also been shown to have a low risk of hypoglycemia and weight gain.
Examples of DPP-4 inhibitors include sitagliptin, saxagliptin, and linagliptin.
Bariatric surgery
Bariatric surgery is a procedure that promotes weight loss by reducing the size of the stomach or bypassing parts of the digestive tract.
It has been shown to improve glycemic control and reduce the need for medication in people with type 2 diabetes who are obese. Recent studies have shown that bariatric surgery can also have lasting benefits for cardiovascular health, kidney function, and overall quality of life.
Conclusion
The recent advancements in drug development and bariatric surgery have led to improved management of type 2 diabetes and weight loss.
These new treatments target different pathways and mechanisms involved in the development of the disease, providing a range of options for people with type 2 diabetes. Such new treatments hold the potential to substantially reduce the long-term complications associated with type 2 diabetes.
